Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Annals of Hematology
Erschienen in: Annals of Hematology 2/2017

04.11.2016 | Original Article

Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis

verfasst von: Wanhua Zhang, Pu Kuang, He Li, Fengjuan Wang, Yu Wang

Erschienen in: Annals of Hematology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The IKAROS family zinc finger 1 (IKZF1) gene is frequently altered in adults with B cell acute lymphoblastic leukemia (ALL). Although many studies have indicated that IKZF1 alterations might be associated with poor outcomes in adults with ALL, the results remain controversial. A previous meta-analysis demonstrated the negative prognostic significance of IKZF1 deletion in ALL. However, most of the included studies (14 out of 15) were conducted in pediatric patients with ALL, and age was identified as a significant source of heterogeneity. Thus, performing the present meta-analysis provides valuable information to further elucidate the prognostic value of IKZF1 deletion in adults with ALL. Eight studies were identified that had been published prior to August 1, 2016. The studies included a total of 1008 patients. Hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS)/relapse-free survival (RFS)/progression-free survival (PFS)/event-free survival (EFS) were pooled to estimate the prognostic power of IKZF1 deletion. Pooled HRs suggested that IKZF1 deletion had a negative impact on both OS (HR = 1.40, 95% CI 1.13–1.73) and DFS/RFS/PFS/EFS (HR = 1.67, 95% CI 1.28–2.17) in the overall population. Subgroup analyses indicated that IKZF1 deletion could independently predict unfavorable OS (HR = 1.60, 95% CI 1.25–2.06) and DFS/RFS/PFS/EFS (HR = 1.67, 95% CI 1.28–2.17) in BCR-ABL1-negative but not in BCR-ABL1-positive B cell ALL patients. Our meta-analysis suggests that IKZF1 deletion is a poor prognostic factor for adults with B cell ALL and may be more valuable in BCR-ABL1-negative B cell ALL patients.
Literatur
1.
Moorman AV (2016) New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 101(4):407–416CrossRefPubMedPubMedCentral
2.
Dias A, Kenderian SJ, Westin GF et al (2016) Novel therapeutic strategies in acute lymphoblastic leukemia. Curr Hematol Malig Rep 11(4):253–264CrossRefPubMed
3.
Al Ustwani O, Gupta N, Bakhribah H et al (2016) Clinical updates in adult acute lymphoblastic leukemia. Crit Rev Oncol Hematol 99:189–199CrossRefPubMed
4.
5.
Wang H, Ouyang H, Lai L et al (2014) Pathogenesis and regulation of cellular proliferation in acute lymphoblastic leukemia—the role of Ikaros. J Buon 19(1):22–28PubMed
6.
Tokunaga K, Yamaguchi S, Iwanaga E et al (2013) High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia. Eur J Haematol 91(3):201–208CrossRefPubMed
7.
Beldjord K, Chevret S, Asnafi V et al (2014) Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 123(24):3739–3749CrossRefPubMed
8.
Iacobucci I, Storlazzi CT, Cilloni D et al (2009) Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114(10):2159–2167CrossRefPubMed
9.
Martinelli G, Iacobucci I, Storlazzi CT et al (2009) IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 27(31):5202–5207CrossRefPubMed
10.
Clappier E, Grardel N, Bakkus M et al (2015) IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children’s Leukemia Group study 58951. Leukemia 29(11):2154–2161CrossRefPubMed
11.
Olsson L, Ivanov Ofverholm I, Noren-Nystrom U et al (2015) The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol 170(6):847–858CrossRefPubMed
12.
van der Veer A, Zaliova M, Mottadelli F et al (2014) IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123(11):1691–1698CrossRefPubMed
13.
van der Veer A, Waanders E, Pieters R et al (2013) Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122(15):2622–2629CrossRefPubMedPubMedCentral
14.
Olsson L, Castor A, Behrendtz M et al (2014) Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia 28(2):302–310CrossRefPubMed
15.
Asai D, Imamura T, Suenobu S et al (2013) IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Med 2(3):412–419CrossRefPubMedPubMedCentral
16.
Yao QM, Liu KY, Gale RP et al (2016) Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer 16:269CrossRefPubMedPubMedCentral
17.
Fang Q, Zhao X, Li Q et al (2016) IKZF1 alterations and expression of CRLF2 predict prognosis in adult Chinese patients with B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 1–11. doi:10.​1080/​10428194.​2016.​1180682
18.
Ribera J, Morgades M, Zamora L et al (2015) Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer 121(21):3809–3817CrossRefPubMed
19.
Kim M, Park J, Kim DW et al (2015) Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. Bone Marrow Transplant 50(3):354–362CrossRefPubMed
20.
Jia M, Wang ZJ, Li JY et al (2014) The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis. Cancer Biomark 14(6):493–503PubMed
21.
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7), e1000097CrossRefPubMedPubMedCentral
22.
23.
Moorman AV, Schwab C, Ensor HM et al (2012) IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 30(25):3100–3108CrossRefPubMed
24.
Dupuis A, Gaub MP, Legrain M et al (2013) Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia 27(2):503–507CrossRefPubMed
25.
O’Reilly J, Russell LJ, Cooney J et al (2013) Unravelling the prognostic effect of IKZF1 deletions and IGH@-CRLF2 in adult acute lymphoblastic leukaemia. Pathology 45(6):609–612CrossRefPubMed
26.
Mullighan CG, Miller CB, Radtke I et al (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191):110–114CrossRefPubMed
27.
Zaliova M, Zimmermannova O, Dorge P et al (2014) ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia 28(1):182–185CrossRefPubMed
28.
Clappier E, Auclerc MF, Rapion J et al (2014) An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28(1):70–77CrossRefPubMed
29.
Ge Z, Gu Y, Zhao G et al (2016) High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget. doi: 10.18632/oncotarget.10437
30.
Chiaretti S, Brugnoletti F, Messina M et al (2016) CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leuk Res 41:36–42CrossRefPubMed
31.
Yamashita Y, Shimada A, Yamada T et al (2013) IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 60(10):1587–1592CrossRefPubMed
32.
Palmi C, Vendramini E, Silvestri D et al (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 26(10):2245–2253CrossRefPubMed
33.
Pieters R, de Groot-Kruseman H, Van der Velden V et al (2016) Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group. J Clin Oncol 34(22):2591–2601CrossRefPubMed
34.
Short NJ, Jabbour E, Sasaki K et al (2016) Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504–507CrossRefPubMed
35.
Ravandi F, Jorgensen JL, O’Brien SM et al (2016) Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392–400CrossRefPubMed
36.
Borowitz MJ, Wood BL, Devidas M et al (2015) Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood 126(8):964–971CrossRefPubMedPubMedCentral
37.
Salek C, Folber F, Fronkova E et al (2016) Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Eur J Haematol 96(3):276–284CrossRefPubMed
38.
Marke R, Havinga J, Cloos J et al (2016) Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 30(7):1599–1603CrossRefPubMed
39.
Vitanza NA, Zaky W, Blum R et al (2014) Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer 61(10):1779–1785CrossRefPubMedPubMedCentral
40.
41.
Song C, Gowda C, Pan X et al (2015) Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood 126(15):1813–1822CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis
verfasst von
Wanhua Zhang
Pu Kuang
He Li
Fengjuan Wang
Yu Wang
Publikationsdatum
04.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 2/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2869-6

Weitere Artikel der Ausgabe 2/2017

Annals of Hematology 2/2017 Zur Ausgabe

Original Article

Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP

Original Article

The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group

Letter to the Editor

The importance of erythroblast enumeration in myeloid neoplasia

Original Article

Microparticles from splenectomized β-thalassemia/HbE patients play roles on procoagulant activities with thrombotic potential

Letter to the Editor

Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis

Letter to the Editor

HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise